HeHuangMD

Pathology • Dallas, TX

Anatomic Pathology, Clinical Pathology

Physician

Join to view full profile

Dr. Huang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Huang's full profile

Already have an account?

Office
Baylor University Medical Center, Pathology
Dallas, TX 75246

Education & Training

University of Texas M.D. Anderson Cancer CenterSelective Pathology, 2014 - 2016
University at BuffaloResidency, Pathology-Anatomic and Clinical, 2010 - 2014
McGill UniversityPhD, Experimental Medicine, 1998 - 2003
Peking Union Medical CollegeClass of 1997

Certifications & Licensure

CA State Medical License 2024 - 2026
TX State Medical License 2016 - 2026
PA State Medical License 2013 - 2014
American Board of Pathology Pathology - Anatomic/Pathology - Clinical

Awards, Honors, & Recognition

The Adrian O. Vladutiu Award for Excellence University at Buffalo, 2014
Postdoctoral Fellowship Canadian Institutes of Health Research, 2005-2007
Dean's Honor List McGill University, 2004

Clinical Trials

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies Start of enrollment: 2018 May 23
Recruiting
Early Phase 1
Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study Start of enrollment: 2020 Jun 18
Recruiting
Not Applicable
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies Start of enrollment: 2020 Nov 01
Recruiting
Early Phase 1
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL Start of enrollment: 2020 Aug 23
Recruiting
Early Phase 1
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies Start of enrollment: 2020 Nov 01
Recruiting
Early Phase 1
A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy Start of enrollment: 2020 Dec 31
Not yet recruiting
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

634 citations
A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation.
Xin Zeng, Keiko Tamai, Brad Doble, Shitao Li, He Huang
Nature. 2005-12-08
171 citations
Inhibition of GSK3 Phosphorylation of β-Catenin via Phosphorylated PPPSPXS Motifs of Wnt Coreceptor LRP6
Geng Wu, He Huang, José G. Abreu, Xi He
Plos One. 2009-03-18
83 citations
Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer
Charles C. Guo, Tadeusz Majewski, Li Zhang, Hui Yao, Jolanta Bondaruk
Cell Reports. 2019-05-07

Journal Articles

Prostatic Ductal Adenocarcinoma Exhibits More Advanced Histopathological Features than Acinar Adenocarcinoma
He Huang, Frank Chen, North American Journal of Medical and Science, 10/2012
Gastrointestinal Stromal Tumors: Clinicopathology and Advances in Molecular Pathogenesis
He Huang, Franck Chen, North American Journal of Medical and Science, 4/2012
Case report: Pulmonary Benign Metastasizing Leiomyoma appears 26 years after resection of uterine leiomyoma
He Huang, Lucia Balos, Frank Chen, North American Journal of Medical and Science, 1/2012

Professional Memberships

United States and Canadian Academy of Pathology - USCAP
Member
Texas Medical Association - TMA
Member
International Society of Urological Pathology
Member